- GSK180736A
-
- $35.00 / 1mg
-
2026-04-21
- CAS:817194-38-0
- Min. Order:
- Purity: 98.98%
- Supply Ability: 10g
|
| | 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide Basic information |
| Product Name: | 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide | | Synonyms: | 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide;GSK180736A;CS-2541;GRK2 inhibitor GS180736A;GSK180736;GSK180736A (GSK180736);5-Pyrimidinecarboxamide, 4-(4-fluorophenyl)-1,2,3,4-tetrahydro-N-1H-indazol-5-yl-6-methyl-2-oxo-;GSK180736A >=98% (HPLC) | | CAS: | 817194-38-0 | | MF: | C19H16FN5O2 | | MW: | 365.36 | | EINECS: | | | Product Categories: | API | | Mol File: | 817194-38-0.mol |  |
| | 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:57.67(Max Conc. mg/mL);157.83(Max Conc. mM)
Ethanol:3.0(Max Conc. mg/mL);8.21(Max Conc. mM) | | form | A crystalline solid | | color | Light yellow to khaki | | InChI | 1S/C19H16FN5O2/c1-10-16(17(24-19(27)22-10)11-2-4-13(20)5-3-11)18(26)23-14-6-7-15-12(8-14)9-21-25-15/h2-9,17H,1H3,(H,21,25)(H,23,26)(H2,22,24,27) | | InChIKey | HEAIGWIZTYAQTC-UHFFFAOYSA-N | | SMILES | O=C(NC1=CC=C(NN=C2)C2=C1)C3=C(C)NC(NC3C4=CC=C(F)C=C4)=O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide Usage And Synthesis |
| Uses | GSK180736A is potent Rho-associated coiled-coil kinase 1 (ROCK1) inhibitor with an IC50 of 100 nM. GSK180736A is also a selective and ATP-competitive G protein-coupled receptor kinase 2 (GRK2) inhibitor with an IC50 of 0.77 μM. | | Biological Activity | GSK180736A (GSK180736) is a Rho-related, coiled-coil protein kinase inhibitor that binds to GRK2 (G protein-coupled receptor kinase 2) with logIC50 of -6.6. The selectivity for GRK2 is more than 400-fold higher than that for GRK1 and GRK5. | | in vitro | GSK180736A inhibits GRK2 with IC50 of 770 nM, 300-fold more potent than GRK5. It is a weak PKA inhibitor with IC50=30 μM; it is a potent ROCK1 inhibitor (IC50=100 nM). | | target | | Target | Value | ROCK
(Cell-free assay) | 100 nM | GRK2
(Cell-free assay) | 6.6(pIC50) | | IC 50 | ROCK1: 100 nM (IC50); GRK2: 770 nM (IC50) | | References | [1] Waldschmidt HV, et al. Structure-Based Design, Synthesis, and Biological Evaluation of Highly Selective and Potent G Protein-Coupled Receptor Kinase 2 Inhibitors. J Med Chem. 2016 Apr 28;59(8):3793-807. DOI:10.1021/acs.jmedchem.5b02000 |
| | 4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide Preparation Products And Raw materials |
|
|
Tag:4-(4-fluorophenyl)-N-(1H-indazol-5-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide(817194-38-0)
Related Product Information
|
|
daprodustat
N-((S)-1-(4-((S)-2-(2,4-dichlorophenylsulfonaMido)-3-hydroxypropanoyl)piperazin-1-yl)-4-Methyl-1-oxopentan-2-yl)benzo[b]thiophene-2-carboxaMide
GSK-2126458
ABT 702 Dihydrochloride
Danirixin
GSK1940029
GSK 189254A
GSK2110183
gsk2200150a
4-Methoxy-N-(2,4,6-triMethylphenyl)benzenesulfonaMide, 97%
|
According to the laws, regulations and policies related to "patent products", the sale of this product is prohibited!
ChemicalBook prompt
The patent owner or licensee of the product has not released any relevant information for the time being.
|